PepGen Inc. Faces Legal Investigation Over Investor Claims

Author: Addison Perry Updated: 07-16-2025 12:02 PM

Legal Investigation into PepGen Inc.

Investors of PepGen Inc. are facing unsettling times as a legal investigation unfolds regarding potential claims against the company. The law firm Faruqi & Faruqi, LLP is at the forefront, encouraging those who have suffered losses exceeding $50,000 to reach out for assistance.

Understanding the Claims Against PepGen

The concerns stem from alleged securities laws violations committed by PepGen executives. The investigation points to deceptive statements that may have misled investors about the efficacy and safety of PGN-EDO51, an experimental drug aimed at treating Duchenne Muscular Dystrophy (DMD). The complaint highlights that PepGen may have overstated their drug's clinical, regulatory, and commercial prospects.

Details of the Allegations

According to the details available, PepGen may not have been forthcoming about the risks associated with PGN-EDO51 and its clinical trial CONNECT2. Investors were notably led to believe that the drug's effectiveness was greater than what the evidence suggested. This misinformation could have resulted in significant financial losses for many investors, prompting the investigation into the company's practices.

Recent Events Impacting PepGen

In recent months, reports of setbacks have surfaced concerning PepGen's trials. A press release on July 30, 2024, revealed that the results from the CONNECT1 study did not meet investor expectations regarding dystrophin levels, leading to a substantial drop in PepGen's stock price. This revelation deepened investor concerns about the company's future and its commitment to transparency.

Market Response

The news triggered a significant decline in stock value, with a reported drop of 32.69%. Subsequently, on December 16, 2024, the FDA issued a clinical hold notice for the IND application regarding the CONNECT2 study. This hold raised alarms among shareholders about the viability of PepGen's ongoing projects.

Investor Rights and Legal Options

Faruqi & Faruqi emphasizes that any investor affected by these developments should consider their legal options seriously. With the August deadline approaching for seeking lead plaintiff status in a federal securities class action, those impacted need to act swiftly. Investors can contact Faruqi & Faruqi directly to discuss potential claims or share relevant information concerning PepGen's operations.

The Future of PepGen

As the investigation continues, the outcomes remain uncertain, but the implications for PepGen and its investors are significant. It is crucial for individuals who believe they have been affected to stay informed and seek legal guidance to navigate this challenging time.

Frequently Asked Questions

What is the investigation about PepGen?

The investigation concerns potential securities law violations by PepGen executives, particularly in relation to misleading statements regarding the PGN-EDO51 drug.

How can affected investors take action?

Investors who have sustained losses exceeding $50,000 can contact Faruqi & Faruqi for assistance and to discuss legal options related to the investigation.

What has caused PepGen's stock price to decline?

Several announcements regarding clinical trial results that did not meet expectations, along with a clinical hold notice from the FDA, have contributed to the decline in stock price.

What is the deadline for seeking lead plaintiff status?

The deadline for investors to file for lead plaintiff status is upcoming and should be prioritized by those looking to initiate legal action.

Who should I contact for more information?

For further information, investors can contact Faruqi & Faruqi directly through their provided contact details.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.